<p>Artisan Partners Limited Partnership 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第二季度减少了对 Replimune Group, Inc.（NASDAQ:REPL - 免费报告）股份的持有，降幅为 9.5%。该机构投资者在季度内出售了 53,704 股后，持有该公司 511,371 股股票。Artisan Partners Limited Partnership 在最近一个季度末持有的 Replimune Group 的股份约占 0.66%，价值 4,751,000 美元。</p>
<p>获取 <strong>Replimune Group</strong> 警报：</p>
<ul>
<li>按表现排名的最佳股票选择 AI</li>
</ul>
<p>其他几家对冲基金最近也买卖了该公司的股票。Letko Brosseau &amp; Associates Inc. 在第二季度购买了价值约 100,000 美元的 Replimune Group 新头寸。Candriam S.C.A. 在第二季度购买了价值约 1,594,000 美元的 Replimune Group 新股份。Nan Fung Trinity HK Ltd. 在第二季度购买了价值 4,325,000 美元的 Replimune Group 新头寸。洛杉矶资本管理公司在第二季度购买了价值约 403,000 美元的 Replimune Group 新股份。最后，AlphaQuest LLC 在第二季度将其在 Replimune Group 的持股增加了 99.9%。AlphaQuest LLC 现在拥有 9,857 股该公司的股票，价值 92,000 美元，此前在上个季度又收购了 4,925 股。机构投资者持有该公司 92.53% 的股票。</p>
<h2>Replimune Group 股票上涨 2.1%</h2>
<p>NASDAQ:REPL 周五开盘价为 9.20 美元。该公司的债务与股本比率为 0.26，速动比率为 6.31，流动比率为 6.31。该公司的市值为 7.2165 亿美元，市盈率为 -2.66，贝塔值为 0.80。Replimune Group, Inc. 的一年低点为 2.68 美元，一年高点为 17.00 美元。该股票的 50 天简单移动平均线为 6.75 美元，200 天简单移动平均线为 7.40 美元。</p>
<p>Replimune Group（NASDAQ:REPL - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告的每股收益（EPS）为 -0.90，低于市场共识预期的 -0.87，差距为 -0.03。卖方分析师预测 Replimune Group, Inc. 本财年的每股收益将为 -2.97。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票分析师对 REPL 股票发布了报告。Leerink Partners 将 Replimune Group 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并在 10 月 20 日的研究报告中将其目标价从 3.00 美元提高至 13.00 美元。摩根大通将 Replimune Group 的股票评级从 “减持” 上调至 “中性”，并在 10 月 20 日的研究报告中设定了 11.00 美元的目标价。Wedbush 将 Replimune Group 的股票评级从 “中性” 上调至 “跑赢大盘”，并在 10 月 20 日的报告中将其目标价从 4.00 美元提高至 18.00 美元。Piper Sandler 将 Replimune Group 的评级从 “中性” 上调至 “增持”，并在 10 月 20 日的报告中设定了 13.00 美元的目标价。最后，HC Wainwright 将 Replimune Group 的评级从 “中性” 上调至 “买入”，并在 10 月 27 日的研究报告中设定了 12.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，Replimune Group 目前的共识评级为 “适度买入”，平均目标价为 9.75 美元。</p>
<p><strong>查看我们最新的 Replimune Group 股票分析</strong></p>
<h2>Replimune Group 的内部买卖</h2>
<p>在相关消息中，内部人士 Konstantinos Xynos 于 11 月 17 日星期一出售了 7,248 股该公司的股票。股票以平均价格 9.10 美元出售，总价值为 65,956.80 美元。交易后，该内部人士直接持有该公司 139,685 股股票，价值约 1,271,133.50 美元。此交易代表其持股减少了 4.93%。该交易已在 SEC 的文件中披露，相关信息可通过此链接获取。此外，内部人士 Christopher Sarchi 于 11 月 17 日星期一出售了 5,208 股 Replimune Group 股票。该股票以平均价格 9.10 美元出售，总交易额为 47,392.80 美元。出售后，该内部人士持有该公司 123,088 股股票，价值 1,120,100.80 美元。这代表其持股减少了 4.06%。有关此交易的更多细节可在官方 SEC 披露中找到。公司内部人士持有该公司 5.20% 的股票。</p>
<h2>Replimune Group 公司简介</h2>
<p>（免费报告）</p>
<p>Replimune Group, Inc. 是一家临床阶段的生物技术公司，专注于开发肿瘤溶解免疫疗法以治疗癌症。该公司的专有肿瘤定向溶解免疫疗法产品候选旨在激活免疫系统对抗癌症。其主要产品候选是 RP1，一种选择性复制的 HSV-1 版本，表达 GALV-GP R(-) 和人类 GM-CSF，目前正在进行针对多种实体瘤的 I/II 期临床试验；并已完成针对皮肤鳞状细胞癌的 II 期临床试验。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Replimune Group 更好</li>
<li>投资于建筑股票</li>
<li>一项宏伟的 AI 投资？斯坦利·德鲁肯米勒的最新科技动态</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Replimune Group 吗？</h2>
<p>在考虑 Replimune Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Replimune Group 并不在名单上。</p>
<p>虽然 Replimune Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

REPL

Artisan合伙资产管理

<p>Artisan Partners Limited Partnership 在第二季度减少了对 Replimune Group, Inc. 的持股比例，下降了 9.5%，目前持有 511,371 股，价值 475 万美元。Replimune 的股票开盘价为 9.20 美元，市值为 7.2165 亿美元。分析师的评级意见不一，普遍共识为 “适度买入”，目标价格为 9.75 美元。同时也有内部人士出售股票的报告</p>

<p>Artisan Partners Limited Partnership decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 9.5% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 511,371 shares of the company's stock after selling 53,704 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.66% of Replimune Group worth $4,751,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Artisan Partners Limited Partnership 在最近向美国证券交易委员会（SEC）提交的文件中表示，在第二季度减少了对 Replimune Group, Inc.（NASDAQ:REPL - 免费报告）股份的持有，降幅为 9.5%。该机构投资者在季度内出售了 53,704 股后，持有该公司 511,371 股股票。Artisan Partners Limited Partnership 在最近一个季度末持有的 Replimune Group 的股份约占 0.66%，价值 4,751,000 美元。</p>
</div><p>Get <strong>Replimune Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Replimune Group</strong> 警报：</p>
</div><ul>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>按表现排名的最佳股票选择 AI</li>
</ul>
</div><p>Several other hedge funds also recently bought and sold shares of the company. Letko Brosseau &amp; Associates Inc. purchased a new position in Replimune Group during the 2nd quarter valued at approximately $100,000. Candriam S.C.A. purchased a new stake in shares of Replimune Group during the 2nd quarter valued at approximately $1,594,000. Nan Fung Trinity HK Ltd. purchased a new position in Replimune Group in the second quarter valued at $4,325,000. Los Angeles Capital Management LLC purchased a new stake in Replimune Group during the 2nd quarter worth about $403,000. Finally, AlphaQuest LLC raised its stake in Replimune Group by 99.9% during the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company's stock worth $92,000 after acquiring an additional 4,925 shares in the last quarter. Institutional investors own 92.53% of the company's stock.</p>
<div class="lb-trans"><p>其他几家对冲基金最近也买卖了该公司的股票。Letko Brosseau &amp; Associates Inc. 在第二季度购买了价值约 100,000 美元的 Replimune Group 新头寸。Candriam S.C.A. 在第二季度购买了价值约 1,594,000 美元的 Replimune Group 新股份。Nan Fung Trinity HK Ltd. 在第二季度购买了价值 4,325,000 美元的 Replimune Group 新头寸。洛杉矶资本管理公司在第二季度购买了价值约 403,000 美元的 Replimune Group 新股份。最后，AlphaQuest LLC 在第二季度将其在 Replimune Group 的持股增加了 99.9%。AlphaQuest LLC 现在拥有 9,857 股该公司的股票，价值 92,000 美元，此前在上个季度又收购了 4,925 股。机构投资者持有该公司 92.53% 的股票。</p>
</div><h2>Replimune Group Stock Up 2.1%</h2>
<div class="lb-trans"><h2>Replimune Group 股票上涨 2.1%</h2>
</div><p>NASDAQ:REPL opened at $9.20 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31. The company has a market capitalization of $721.65 million, a price-to-earnings ratio of -2.66 and a beta of 0.80. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $17.00. The stock has a 50-day simple moving average of $6.75 and a 200 day simple moving average of $7.40.</p>
<div class="lb-trans"><p>NASDAQ:REPL 周五开盘价为 9.20 美元。该公司的债务与股本比率为 0.26，速动比率为 6.31，流动比率为 6.31。该公司的市值为 7.2165 亿美元，市盈率为 -2.66，贝塔值为 0.80。Replimune Group, Inc. 的一年低点为 2.68 美元，一年高点为 17.00 美元。该股票的 50 天简单移动平均线为 6.75 美元，200 天简单移动平均线为 7.40 美元。</p>
</div><p>Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Sell-side analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Replimune Group（NASDAQ:REPL - 获取免费报告）最近于 11 月 6 日星期四发布了季度财报。该公司报告的每股收益（EPS）为 -0.90，低于市场共识预期的 -0.87，差距为 -0.03。卖方分析师预测 Replimune Group, Inc. 本财年的每股收益将为 -2.97。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities analysts have issued reports on REPL shares. Leerink Partners raised shares of Replimune Group from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and boosted their price objective for the company from $3.00 to $13.00 in a research note on Monday, October 20th. JPMorgan Chase &amp; Co. upgraded shares of Replimune Group from an &#34;underweight&#34; rating to a &#34;neutral&#34; rating and set a $11.00 price target on the stock in a research note on Monday, October 20th. Wedbush raised shares of Replimune Group from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their price target for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Piper Sandler raised Replimune Group from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and set a $13.00 price objective on the stock in a report on Monday, October 20th. Finally, HC Wainwright upgraded Replimune Group from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $12.00 target price on the stock in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Replimune Group presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $9.75.</p>
<div class="lb-trans"><p>几位股票分析师对 REPL 股票发布了报告。Leerink Partners 将 Replimune Group 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并在 10 月 20 日的研究报告中将其目标价从 3.00 美元提高至 13.00 美元。摩根大通将 Replimune Group 的股票评级从 “减持” 上调至 “中性”，并在 10 月 20 日的研究报告中设定了 11.00 美元的目标价。Wedbush 将 Replimune Group 的股票评级从 “中性” 上调至 “跑赢大盘”，并在 10 月 20 日的报告中将其目标价从 4.00 美元提高至 18.00 美元。Piper Sandler 将 Replimune Group 的评级从 “中性” 上调至 “增持”，并在 10 月 20 日的报告中设定了 13.00 美元的目标价。最后，HC Wainwright 将 Replimune Group 的评级从 “中性” 上调至 “买入”，并在 10 月 27 日的研究报告中设定了 12.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，两位给予 “持有” 评级，两位给予 “卖出” 评级。根据 MarketBeat 的数据，Replimune Group 目前的共识评级为 “适度买入”，平均目标价为 9.75 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Replimune Group</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Replimune Group 股票分析</strong></p>
</div><h2>Insider Buying and Selling at Replimune Group</h2>
<div class="lb-trans"><h2>Replimune Group 的内部买卖</h2>
</div><p>In related news, insider Konstantinos Xynos sold 7,248 shares of the firm's stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the transaction, the insider directly owned 139,685 shares in the company, valued at approximately $1,271,133.50. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Christopher Sarchi sold 5,208 shares of Replimune Group stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $47,392.80. Following the sale, the insider owned 123,088 shares in the company, valued at $1,120,100.80. This represents a 4.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 5.20% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Konstantinos Xynos 于 11 月 17 日星期一出售了 7,248 股该公司的股票。股票以平均价格 9.10 美元出售，总价值为 65,956.80 美元。交易后，该内部人士直接持有该公司 139,685 股股票，价值约 1,271,133.50 美元。此交易代表其持股减少了 4.93%。该交易已在 SEC 的文件中披露，相关信息可通过此链接获取。此外，内部人士 Christopher Sarchi 于 11 月 17 日星期一出售了 5,208 股 Replimune Group 股票。该股票以平均价格 9.10 美元出售，总交易额为 47,392.80 美元。出售后，该内部人士持有该公司 123,088 股股票，价值 1,120,100.80 美元。这代表其持股减少了 4.06%。有关此交易的更多细节可在官方 SEC 披露中找到。公司内部人士持有该公司 5.20% 的股票。</p>
</div><h2>Replimune Group Company Profile</h2>
<div class="lb-trans"><h2>Replimune Group 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.</p>
<div class="lb-trans"><p>Replimune Group, Inc. 是一家临床阶段的生物技术公司，专注于开发肿瘤溶解免疫疗法以治疗癌症。该公司的专有肿瘤定向溶解免疫疗法产品候选旨在激活免疫系统对抗癌症。其主要产品候选是 RP1，一种选择性复制的 HSV-1 版本，表达 GALV-GP R(-) 和人类 GM-CSF，目前正在进行针对多种实体瘤的 I/II 期临床试验；并已完成针对皮肤鳞状细胞癌的 II 期临床试验。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Replimune Group</li>
<li>Investing in Construction Stocks</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Replimune Group 更好</li>
<li>投资于建筑股票</li>
<li>一项宏伟的 AI 投资？斯坦利·德鲁肯米勒的最新科技动态</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>股票分析师评级和加拿大分析师评级</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVQTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REPL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Replimune Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Replimune Group 吗？</h2>
</div><p>Before you consider Replimune Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Replimune Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Replimune Group 并不在名单上。</p>
</div><p>While Replimune Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Replimune Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Artisan 合伙有限合伙公司减少了其在 Replimune Group, Inc. $REPL 的持股量